Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CymaBay Therapeutics
CymaBay Therapeutics
Gilead's new liver disease med continues to deliver the goods ahead of FDA verdict
Fierce Biotech
Mon, 05/20/24 - 10:59 am
Gilead Sciences
CymaBay Therapeutics
seladelpar
liver disease
Biopharma M&A activity jumped 71% in Q1 2024
Medical Marketing and Media
Thu, 05/16/24 - 11:37 am
M&A
Novo Nordisk
Catalent
Gilead Sciences
CymaBay Therapeutics
AstraZeneca
Fusion Pharmaceuticals
JNJ
Ambrx
Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24
Fierce Biotech
Wed, 04/3/24 - 11:36 am
biotech
M&A
IPOs
CG Oncology
Kyverna Therapeutics
Contineum Therapeutics
Boundless Bio
CymaBay Therapeutics
Gilead Sciences
MorphoSys
Novartis
Fusion Pharmaceuticals
AstraZeneca
Ambryx
JNJ
Inhibrix
Aventis
Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
Fierce Biotech
Mon, 02/12/24 - 11:53 am
Gilead Sciences
CymaBay Therapeutics
M&A
liver disease
seladelpar
primary biliary cholangitis
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Tue, 11/14/23 - 09:20 am
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
2 NASH drugmakers have wildly different Mondays
Biopharma Dive
Mon, 11/25/19 - 10:11 pm
Intercept Pharmaceuticals
CymaBay Therapeutics
FDA
NASH
seladelpar
obeticholic acid
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Motley Fool
Wed, 10/23/19 - 10:40 am
liver disease
NASH
The Liver Meeting
Assembly Biosciences
CymaBay Therapeutics
Madrigal Pharmaceuticals